Neonc Technologies (NASDAQ:NTHI) Rating Lowered to “Strong Sell” at Zacks Research

Posted by George Bondi on Oct 9th, 2026

Neonc Technologies (NASDAQ:NTHI – Get Free Report) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Several other analysts have also recently commented on NTHI. Weiss Ratings raised Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Roth Capital started coverage on Neonc Technologies in a report on Thursday, September 24th. They set a “buy” rating on the stock. Wall Street Zen cut Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Neonc Technologies in a report on Tuesday, September 8th. Four analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Neonc Technologies has a consensus rating of “Hold” and an average target price of $16.00.

Check Out Our Latest Research Report on Neonc Technologies

Neonc Technologies Stock Performance

Shares of NASDAQ:NTHI opened at $2.53 on Wednesday. Neonc Technologies has a 52 week low of $2.52 and a 52 week high of $12.10. The company has a 50-day moving average price of $3.84 and a 200 day moving average price of $4.55.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Insiders Place Their Bets

In other news, CEO Amir F. Heshmatpour purchased 35,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was acquired at an average price of $3.30 per share, for a total transaction of $115,500.00. Following the completion of the transaction, the chief executive officer directly owned 3,183,000 shares in the company, valued at $10,503,900. This represents a 1.11% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas C. Chen purchased 12,757 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were purchased at an average cost of $5.49 per share, with a total value of $70,035.93. Following the purchase, the chief executive officer directly owned 13,705 shares in the company, valued at approximately $75,240.45. The trade was a 1,345.68% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 134,812 shares of company stock worth $530,149.

Institutional Investors Weigh In On Neonc Technologies

A number of large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new stake in shares of Neonc Technologies in the second quarter valued at approximately $1,017,000. BlackRock Inc. purchased a new position in shares of Neonc Technologies during the 2nd quarter worth approximately $815,000. Westmount Partners LLC raised its position in shares of Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new position in shares of Neonc Technologies during the 2nd quarter worth approximately $126,000.

Neonc Technologies Company Profile

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.